<?xml version="1.0" encoding="UTF-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:space="preserve" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania</title>
				<funder ref="#_naXtzFE">
					<orgName type="full">Tehran University of Medical Sciences</orgName>
				</funder>
				<funder>
					<orgName type="full">Iranian Board of Psychiatry</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher />
				<availability status="unknown">
					<licence />
				</availability>
				<date type="published" when="2010-09-16">16 September 2010</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Zohreh</forename><surname>Amrollahi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Psychiatric Research Center</orgName>
								<orgName type="institution" key="instit1">Roozbeh Hospital</orgName>
								<orgName type="institution" key="instit2">Tehran University of Medical Sciences</orgName>
								<address>
									<settlement>Tehran</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Farzin</forename><surname>Rezaei</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Qods Hospital</orgName>
								<orgName type="institution" key="instit2">Kurdistan University of Medical Sciences</orgName>
								<address>
									<settlement>Sanandaj</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bahman</forename><surname>Salehi</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">Shaheed Hashemi Senejani Hospital</orgName>
								<orgName type="institution" key="instit2">Arak University of Medical Sciences</orgName>
								<address>
									<settlement>Arak</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Amir-Hossein</forename><surname>Modabbernia</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Psychiatric Research Center</orgName>
								<orgName type="institution" key="instit1">Roozbeh Hospital</orgName>
								<orgName type="institution" key="instit2">Tehran University of Medical Sciences</orgName>
								<address>
									<settlement>Tehran</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Azad</forename><surname>Maroufi</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Qods Hospital</orgName>
								<orgName type="institution" key="instit2">Kurdistan University of Medical Sciences</orgName>
								<address>
									<settlement>Sanandaj</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gholam-Reza</forename><surname>Esfandiari</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Qods Hospital</orgName>
								<orgName type="institution" key="instit2">Kurdistan University of Medical Sciences</orgName>
								<address>
									<settlement>Sanandaj</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mehrangiz</forename><surname>Naderi</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">Shaheed Hashemi Senejani Hospital</orgName>
								<orgName type="institution" key="instit2">Arak University of Medical Sciences</orgName>
								<address>
									<settlement>Arak</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fariba</forename><surname>Ghebleh</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">Shaheed Hashemi Senejani Hospital</orgName>
								<orgName type="institution" key="instit2">Arak University of Medical Sciences</orgName>
								<address>
									<settlement>Arak</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Seyed-Ali</forename><surname>Ahmadi-Abhari</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Psychiatric Research Center</orgName>
								<orgName type="institution" key="instit1">Roozbeh Hospital</orgName>
								<orgName type="institution" key="instit2">Tehran University of Medical Sciences</orgName>
								<address>
									<settlement>Tehran</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Majid</forename><surname>Sadeghi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Psychiatric Research Center</orgName>
								<orgName type="institution" key="instit1">Roozbeh Hospital</orgName>
								<orgName type="institution" key="instit2">Tehran University of Medical Sciences</orgName>
								<address>
									<settlement>Tehran</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mina</forename><surname>Tabrizi</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Medical Genetics</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">Tehran University of Medical Sciences</orgName>
								<address>
									<settlement>Tehran</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Shahin</forename><surname>Akhondzadeh</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Psychiatric Research Center</orgName>
								<orgName type="institution" key="instit1">Roozbeh Hospital</orgName>
								<orgName type="institution" key="instit2">Tehran University of Medical Sciences</orgName>
								<address>
									<settlement>Tehran</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">Psychiatric Research Center</orgName>
								<orgName type="institution" key="instit1">Roozbeh Psychiatric Hospital</orgName>
								<orgName type="institution" key="instit2">Tehran University of Medical Sciences</orgName>
								<address>
									<addrLine>South Kargar Street</addrLine>
									<postCode>13337</postCode>
									<settlement>Tehran</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2010-09-16">16 September 2010</date>
						</imprint>
					</monogr>
					<idno type="MD5">1FA0904827245D17097F0A45A8F4E799</idno>
					<idno type="DOI">10.1016/j.jad.2010.08.015</idno>
					<note type="submission">Received 2 June 2010 Received in revised form 17 August 2010 Accepted 17 August 2010</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-11-26T12:22+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=0, consolidateHeader=0, consolidateFunders=0, includeRawAffiliations=false, includeRawCitations=false, includeRawCopyrights=false, generateTeiIds=false, generateTeiCoordinates=[s, figure, ref, biblStruct], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid" />
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>Lithium Mania Protein kinase C Tamoxifen</keywords>
			</textClass>
			<abstract>
<div xml:id="abs-d1"><p xml:id="abs-d1-p1"><s coords="1,195.59,330.76,307.55,7.34;1,195.59,340.34,253.12,7.28" xml:id="abs-d1-p1-s1">Background: Considerable amount of biochemical data supports the potential involvement of protein kinase C in the pathophysiology and treatment of bipolar disorder.</s><s coords="1,451.61,340.34,51.51,7.28;1,195.59,349.87,307.55,7.28;1,195.59,359.45,307.50,7.28;1,195.59,369.03,28.06,7.28" xml:id="abs-d1-p1-s2">The aim of this double-blind, placebo-controlled study was to investigate the efficacy and tolerability of tamoxifen as an adjunct to lithium for the treatment of acute mania in hospitalized bipolar patients.</s><s coords="1,195.59,378.61,307.52,7.28;1,195.59,388.14,80.04,7.28" xml:id="abs-d1-p1-s3">Methods: Eligible participants were 40 inpatients, between the ages of 19 and 49 years with current manic episode.</s><s coords="1,280.18,388.14,222.99,7.28;1,195.59,397.72,307.51,7.28;1,195.59,407.30,132.08,7.28" xml:id="abs-d1-p1-s4">Patients were randomly allocated to lithium (1-1.2 mEq/L) + tamoxifen 80 mg/day (group A) or lithium (1-1.2 mEq/L) + placebo (group B) for a 6-week, double-blind, placebo-controlled study.</s><s coords="1,331.09,407.30,172.05,7.28;1,195.59,416.82,63.90,7.28" xml:id="abs-d1-p1-s5">The principal measure of outcome was the Young Mania Rating Scale.</s><s coords="1,261.70,416.82,237.04,7.28" xml:id="abs-d1-p1-s6">The raters used standardized instructions for Young Mania Rating Scale.</s><s coords="1,195.59,426.40,217.48,7.28" xml:id="abs-d1-p1-s7">Results: Young Mania Rating Scale scores improved with tamoxifen.</s><s coords="1,414.65,426.40,88.46,7.28;1,195.59,435.98,307.57,7.28;1,195.59,445.51,110.86,7.28" xml:id="abs-d1-p1-s8">The difference between the two protocols was significant as indicated by the effect of the group, the between-subjects factor (F = 5.41, df =1, p = 0.02).</s><s coords="1,309.32,445.51,193.83,7.28;1,195.59,455.09,215.45,7.28" xml:id="abs-d1-p1-s9">A significant difference was observed on the Positive and Negative Syndrome Scale total score at week 6 in the two groups.</s><s coords="1,413.12,455.09,89.99,7.28;1,195.59,464.67,307.51,7.28;1,195.59,474.25,116.50,7.28" xml:id="abs-d1-p1-s10">The difference between the two groups in the frequency of side effects was not significant except for fatigue that occurred more often in the tamoxifen group.</s><s coords="1,195.59,483.78,223.91,7.28" xml:id="abs-d1-p1-s11">Limitations: Tamoxifen is an antagonist of estrogen receptor as well.</s></p></div>
<div xml:id="abs-d2"><head xml:id="abs-d2-h1">Conclusion:</head><p xml:id="abs-d2-p1"><s coords="1,235.50,493.36,267.64,7.28;1,195.59,502.94,234.48,7.28" xml:id="abs-d2-p1-s1">The results demonstrate that the combination of tamoxifen with lithium was superior to lithium alone for the rapid reduction of manic symptoms.</s><s coords="1,432.85,502.94,70.29,7.28;1,195.59,512.46,246.50,7.28" xml:id="abs-d2-p1-s2">The combined use of tamoxifen with lithium was well tolerated in these acutely manic patients.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="544.309" lry="742.28" />
		<surface n="2" ulx="0.0" uly="0.0" lrx="544.309" lry="742.28" />
		<surface n="3" ulx="0.0" uly="0.0" lrx="544.309" lry="742.28" />
		<surface n="4" ulx="0.0" uly="0.0" lrx="544.309" lry="742.28" />
		<surface n="5" ulx="0.0" uly="0.0" lrx="544.309" lry="742.28" />
	</facsimile>
	<text xml:lang="en">
		<body>
<div xml:id="d1"><head n="1." xml:id="d1-h1">Introduction</head><p xml:id="d1-p1"><s coords="1,48.81,591.81,209.22,8.09;1,36.85,602.25,221.20,8.09;1,281.93,572.88,221.17,8.09;1,281.93,583.31,180.97,8.09" xml:id="d1-p1-s1">Protein kinase C (PKC) represents a family of enzymes highly enriched in brain, where it plays a major role in regulating both pre-and post-synaptic aspects of neurotransmission (DiazGranados and <ref type="bibr" coords="1,409.78,583.31,49.10,8.09" target="#b5">Zarate, 2008)</ref>.</s><s coords="1,466.41,583.31,36.70,8.09;1,281.94,593.80,221.20,8.09;1,281.94,604.23,221.16,8.09;1,281.94,614.72,221.15,8.09;1,281.94,625.15,24.13,8.09" xml:id="d1-p1-s2">Abundant evidence has accumulated to show that activation of PKC enhances release of dopamine, a neurotransmitter implicated in the manic syndrome (DiazGranados and <ref type="bibr" coords="1,477.65,614.72,25.44,8.09;1,281.94,625.15,20.11,8.09" target="#b5">Zarate, 2008)</ref>.</s><s coords="1,310.08,625.15,193.01,8.09;1,281.93,635.64,221.16,8.09;1,281.93,646.07,221.16,8.09;1,281.94,656.56,45.16,8.09" xml:id="d1-p1-s3">A converging body of preclinical data has shown that chronic use of lithium and valproate, at therapeutic concentrations, regulates the PKC signaling cascade <ref type="bibr" coords="1,475.95,646.07,27.14,8.09;1,281.94,656.56,41.13,8.09">(Zarate et al., 2007)</ref>.</s><s coords="1,328.84,656.56,174.23,8.09;2,41.22,54.37,221.17,8.09;2,41.22,64.80,149.65,8.09" xml:id="d1-p1-s4">This has led to the investigation of the potential antimanic efficacy of tamoxifen, which at sufficient doses inhibits PKC <ref type="bibr" coords="2,91.37,64.80,95.46,8.09" target="#b11">(Zarate and Manji, 2009)</ref>.</s><s coords="2,194.49,64.80,67.86,8.09;2,41.22,75.29,221.16,8.09;2,41.22,85.72,221.17,8.09;2,41.22,96.21,221.16,8.40;2,41.22,106.69,24.36,8.09" xml:id="d1-p1-s5">Tamoxifen clearly crosses the blood-brain barrier, has efficacy in the treatment of malignant gliomas, and is fairly well tolerated even at high doses (up to 200 mg ⁄ day) (DiazGranados and <ref type="bibr" coords="2,236.89,96.21,25.48,8.09;2,41.22,106.69,20.30,8.09" target="#b5">Zarate, 2008)</ref>.</s><s coords="2,70.55,106.69,191.86,8.09;2,41.22,117.12,221.15,8.09;2,41.22,127.61,221.17,8.09;2,41.22,138.04,221.17,8.09;2,41.22,148.53,68.35,8.09" xml:id="d1-p1-s6">Tamoxifen, among the least toxic of anticancer agents, is the most widely used hormonal therapy for breast cancer, and has been approved as a chemopreventive agent in women at high risk for breast cancer (DiazGranados and <ref type="bibr" coords="2,57.55,148.53,48.01,8.09" target="#b5">Zarate, 2008)</ref>.</s><s coords="2,112.00,148.53,150.38,8.09;2,41.22,158.96,221.17,8.09;2,41.22,169.45,221.12,8.09;2,41.22,179.88,24.13,8.09" xml:id="d1-p1-s7">A small number of trials have suggested possible efficacy of tamoxifen in mania <ref type="bibr" coords="2,200.76,158.96,61.63,8.09;2,41.22,169.45,21.44,8.09">(Bebchuk et al., 2000;</ref><ref type="bibr" coords="2,65.20,169.45,78.42,8.09" target="#b8">Kulkarni et al., 2006;</ref><ref type="bibr" coords="2,146.15,169.45,70.01,8.09">Zarate et al., 2007;</ref><ref type="bibr" coords="2,218.71,169.45,43.63,8.09;2,41.22,179.88,20.11,8.09" target="#b9">Yildiz et al., 2008)</ref>.</s><s coords="2,69.14,179.88,193.27,8.09;2,41.21,190.37,221.16,8.09;2,41.21,200.80,221.19,8.09;2,41.21,211.29,142.33,8.09" xml:id="d1-p1-s8">The four reported trials were in different designs such as open label, montherapy, add-on therapy or placebocontrolled trial <ref type="bibr" coords="2,99.73,200.80,81.89,8.09">(Bebchuk et al., 2000;</ref><ref type="bibr" coords="2,184.04,200.80,78.37,8.09" target="#b8">Kulkarni et al., 2006;</ref><ref type="bibr" coords="2,41.21,211.29,69.84,8.09">Zarate et al., 2007;</ref><ref type="bibr" coords="2,113.48,211.29,66.04,8.09" target="#b9">Yildiz et al., 2008)</ref>.</s><s coords="2,185.97,211.29,76.41,8.09;2,41.22,221.72,221.19,8.09;2,41.22,232.21,175.90,8.09" xml:id="d1-p1-s9">Although the results with tamoxifen as an antimanic agent are encouraging, they need to be confirmed in further studies.</s><s coords="2,220.62,232.21,41.77,8.09;2,41.22,242.64,221.21,8.09;2,41.22,253.13,221.18,8.09;2,41.22,263.56,221.18,8.09;2,41.22,274.05,60.90,8.09" xml:id="d1-p1-s10">The aim of this double-blind, placebo-controlled study was to investigate the efficacy and tolerability of tamoxifen as an adjunct to lithium for the treatment of acute mania in hospitalized bipolar patients.</s></p></div>
<div xml:id="d2"><head n="2." xml:id="d2-h1">Methods</head></div>
<div xml:id="d3"><head n="2.1." xml:id="d3-h1">Trial organization</head><p xml:id="d3-p1"><s coords="2,53.18,336.81,209.23,8.09;2,41.22,347.24,221.22,8.09;2,41.22,357.73,114.05,8.09" xml:id="d3-p1-s1">This was a 6-week, parallel-group, placebo-controlled trial undertaken at three teaching psychiatric hospitals in Iran from March 2010 to May 2010.</s></p></div>
<div xml:id="d4"><head n="3." xml:id="d4-h1">Participants</head><p xml:id="d4-p1"><s coords="2,53.18,399.56,209.22,8.09;2,41.22,410.05,221.18,8.09;2,41.22,420.48,221.19,8.09;2,41.22,430.97,221.13,8.09;2,41.22,441.40,221.19,8.09;2,41.22,451.89,71.07,8.09" xml:id="d4-p1-s1">Eligible participants were 40 inpatients, between the ages of 19 and 49 years with current manic episode (with or without psychotic features) as diagnosed by means of the Structured Clinical Interview for Axis I DSM-IV Disorders-Patient Version (SCID-P) <ref type="bibr" coords="2,178.70,441.40,83.71,8.09;2,41.22,451.89,67.05,8.09">(American Psychiatric Association, 2000)</ref>.</s><s coords="2,114.72,451.89,147.67,8.09;2,41.22,462.32,221.13,8.09;2,41.22,472.81,221.17,8.09;2,41.22,483.24,24.13,8.09" xml:id="d4-p1-s2">In addition, a score of at least 20 points on the Young Mania Rating Scale was required representing at least a moderate-to-severe mania <ref type="bibr" coords="2,207.78,472.81,54.60,8.09;2,41.22,483.24,20.11,8.09" target="#b10">(Young et al., 1978)</ref>.</s><s coords="2,70.89,483.24,191.45,8.09;2,41.22,493.73,221.16,8.09;2,41.22,504.16,221.14,8.09;2,41.22,514.65,221.29,8.40;2,41.22,525.08,221.20,8.09;2,41.22,535.57,221.15,8.09;2,41.22,546.00,221.14,8.40;2,41.22,556.49,221.14,8.09;2,41.22,566.92,221.18,8.09;2,41.22,577.41,221.17,8.09;2,41.22,587.84,221.16,8.09;2,41.22,598.33,221.13,8.09;2,41.22,608.76,221.15,8.09;2,41.22,619.25,108.46,8.09" xml:id="d4-p1-s3">Neurological or other medical impairment; the need for ongoing treatment with other psychoactive medications and/or current substance dependence; mental retardation (IQ b 70); history of renal or liver function impairments; history of coagulopathy, deep vein thrombosis, or pulmonary embolus; known sensitivity to tamoxifen; QTC N 450 ms at screening, seizure disorder requiring medication; participation in an investigational drug trial within 30 days before the start of the trial; known sensitivity to lithium or tamoxifen; use of depot neuroleptics within one cycle before study entry; laboratory values outside the normal range; and women of childbearing potential who were without adequate contraception were the exclusion criteria.</s><s coords="2,154.20,619.25,108.16,8.09;2,41.22,629.68,221.14,8.09;2,41.22,640.17,79.47,8.09" xml:id="d4-p1-s4">The protocol was approved by the Institutional Review Board of Tehran University of Medical Sciences.</s><s coords="2,125.32,640.17,137.06,8.09;2,41.22,650.60,150.66,8.09" xml:id="d4-p1-s5">The trial was performed in accordance with the Declaration of Helsinki.</s><s coords="2,195.04,650.60,67.37,8.09;2,41.22,661.09,202.30,8.09" xml:id="d4-p1-s6">Written informed consents were obtained before entry into the study.</s><s coords="2,246.91,661.09,15.50,8.09;2,41.22,671.52,221.22,8.09;2,41.22,682.01,102.85,8.09" xml:id="d4-p1-s7">This trial is registered with the Iranian Clinical Trials Registry (IRCT1138901151556N12).</s></p></div>
<div xml:id="d5"><head n="4." xml:id="d5-h1">Study design</head><p xml:id="d5-p1"><s coords="2,298.26,75.28,209.22,8.09;2,286.30,85.71,221.16,8.09;2,286.30,96.19,203.93,8.09" xml:id="d5-p1-s1">Forty patients were randomly allocated to lithium (1-1.2 mEq/L)+ tamoxifen or lithium (1-1.2 mEq/L) + placebo for a 6-week, double-blind, placebo-controlled study.</s><s coords="2,493.90,96.19,13.53,8.09;2,286.30,106.69,221.10,8.09;2,286.30,117.13,48.43,8.09" xml:id="d5-p1-s2">The starting dose of tamoxifen citrate was 20 mg twice daily (40 mg/day).</s><s coords="2,337.15,117.13,170.32,8.09;2,286.30,127.61,221.18,8.09;2,286.30,138.05,57.27,8.09" xml:id="d5-p1-s3">Thereafter, daily doses were adjusted upward by 10 mg to achieve 80 mg/day in twice-daily divided doses for all subjects.</s><s coords="2,346.56,138.05,160.91,8.09;2,286.30,148.53,221.18,8.40;2,286.30,158.96,221.20,8.09;2,286.30,169.45,18.72,8.09" xml:id="d5-p1-s4">Concomitant lorazepam use was restricted to a maximum dose of 2 mg/day for the first 4 days of treatment and thereafter by up to 1 mg/day for the next 6 days.</s><s coords="2,308.18,169.45,199.30,8.09;2,286.30,179.88,221.18,8.09;2,286.30,190.37,86.01,8.09" xml:id="d5-p1-s5">Lorazepam use was stopped after the initial 10 days and was not dispensed within 8 h of the administration of the mania rating scale.</s><s coords="2,375.31,190.37,132.16,8.09;2,286.30,200.80,221.18,8.09;2,286.30,211.29,64.30,8.09" xml:id="d5-p1-s6">Patients were assessed by psychiatrist at baseline and at 7, 14, 28 and 42 days after start of medical therapy.</s><s coords="2,355.18,211.29,152.28,8.09;2,286.30,221.72,221.18,8.09;2,286.30,232.21,89.59,8.09" xml:id="d5-p1-s7">All psychotropic medications, with the exception of benzodiazepines, were discontinued at least 48 h before randomization.</s></p></div>
<div xml:id="d6"><head n="5." xml:id="d6-h1">Outcome</head><p xml:id="d6-p1"><s coords="2,298.26,274.05,209.20,8.09;2,286.30,284.48,221.17,8.09;2,286.30,294.97,110.05,8.09" xml:id="d6-p1-s1">The principal measure of the outcome was the Young Mania Rating Scale (YMRS) <ref type="bibr" coords="2,390.90,284.48,73.61,8.09" target="#b10">(Young et al., 1978;</ref><ref type="bibr" coords="2,467.19,284.48,35.80,8.09;2,286.30,294.97,56.01,8.09" target="#b0">Akhondzadeh et al., 1999</ref><ref type="bibr" coords="2,349.17,294.97,16.35,8.09" target="#b1">Akhondzadeh et al., , 2003</ref><ref type="bibr" coords="2,372.43,294.97,19.94,8.09" target="#b2">Akhondzadeh et al., , 2006))</ref>.</s><s coords="2,399.17,294.97,108.29,8.09;2,286.30,305.40,221.18,8.09;2,286.30,315.89,221.17,8.09" xml:id="d6-p1-s2">The mean decrease in Young Mania Rating Scale score from baseline was used as the main outcome measure of response of mania to treatment.</s><s coords="2,286.30,326.32,221.16,8.09;2,286.30,336.81,221.18,8.09;2,286.30,347.24,221.16,8.09;2,286.30,357.73,45.70,8.09" xml:id="d6-p1-s3">The secondary outcome measures were the Hamilton Depression Rating Scale (HAMD-17) and the Positive and Negative Syndrome Scale (PANSS) <ref type="bibr" coords="2,423.72,347.24,65.73,8.09" target="#b6">(Hamilton, 1960;</ref><ref type="bibr" coords="2,493.79,347.24,13.68,8.09;2,286.30,357.73,41.72,8.09" target="#b7">Kay et al., 1987)</ref>.</s><s coords="2,334.15,357.73,173.33,8.09;2,286.30,368.16,221.21,8.09;2,286.30,378.65,221.17,8.09;2,286.30,389.08,34.48,8.09" xml:id="d6-p1-s4">High inter-rater reliability for the SCID [intraclass correlation coefficient (ICC) = 0.90], YMRS (ICC = 0.90), PANSS (ICC = 0.89) and HAMD-17 (ICC = 0.85) were obtained.</s><s coords="2,324.51,389.08,182.89,8.09;2,286.30,399.57,221.17,8.09" xml:id="d6-p1-s5">Patients were randomized to receive tamoxifen or placebo in a 1:1 ratio using a computer-generated code.</s><s coords="2,286.30,410.05,221.09,8.09;2,286.30,420.48,49.54,8.09" xml:id="d6-p1-s6">The assignments were kept in sealed, opaque envelopes until data analysis.</s></p></div>
<div xml:id="d7"><head n="6." xml:id="d7-h1">Safety measures</head><p xml:id="d7-p1"><s coords="2,298.26,462.32,209.18,8.09;2,286.30,472.81,221.18,8.09;2,286.30,483.24,221.18,8.09;2,286.30,493.73,37.45,8.09" xml:id="d7-p1-s1">Side effects were systematically recorded throughout the study and were assessed using a checklist administered by a resident of psychiatry on day 3, 7, 14, 21, 28 and 42 (Table <ref type="table" coords="2,313.61,493.73,3.38,8.09" target="#tab_0">1</ref>).</s><s coords="2,327.48,493.73,179.93,8.09;2,286.30,504.16,221.17,8.09;2,286.30,514.65,19.28,8.09" xml:id="d7-p1-s2">Laboratory tests obtained included a complete blood count with differential and liver and renal function tests.</s></p></div>
<div xml:id="d8"><head n="7." xml:id="d8-h1">Statistical analysis</head><p xml:id="d8-p1"><s coords="2,298.26,556.49,209.22,8.09;2,286.30,566.92,130.30,8.09" xml:id="d8-p1-s1">A two-way repeated measure analysis of variance (timetreatment interaction) was used.</s><s coords="2,421.84,566.92,85.64,8.09;2,286.30,577.41,221.19,8.09;2,286.30,587.84,221.17,8.09;2,286.30,598.33,41.63,8.09" xml:id="d8-p1-s2">The two groups as a between-subjects factor (group) and the four measurements during treatment as the within-subjects factor (time) were considered.</s><s coords="2,332.16,598.33,175.32,8.09;2,286.30,608.76,24.38,8.09" xml:id="d8-p1-s3">This was done for Young Mania Rating Scale scores.</s><s coords="2,313.45,608.76,194.01,8.09;2,286.30,619.25,221.13,8.09;2,286.30,629.68,221.24,8.09;2,286.30,640.17,131.62,8.09" xml:id="d8-p1-s4">In addition, a one-way repeated measure analysis of variance with a two-tailed post hoc Bonferroni mean comparison test was performed on the change of Mania Rating Scale scores from baseline.</s><s coords="2,422.42,640.17,85.06,8.09;2,286.30,650.60,221.21,8.09;2,286.30,661.09,221.18,8.09" xml:id="d8-p1-s5">To compare the score reduction of Young Mania Rating Scale at week 6 with baseline, an unpaired two-sided Student's t-test was used.</s><s coords="2,286.30,671.52,221.17,8.09;2,286.30,682.01,130.49,8.09" xml:id="d8-p1-s6">Results are presented as mean ± SD differences and were considered significant with p ≤ 0.05.</s><s coords="2,418.90,682.01,88.55,8.09;3,36.85,231.82,221.21,8.09;3,36.85,242.25,123.44,8.09" xml:id="d8-p1-s7">To compare the baseline data and frequency of adverse events between the protocols, Fisher's exact test was performed.</s><s coords="3,162.42,242.25,95.64,8.09;3,36.85,252.73,221.19,8.09;3,36.85,263.17,28.28,8.09" xml:id="d8-p1-s8">Intention-to-treat analysis with last observation carried forward procedure was performed.</s><s coords="3,66.67,263.17,191.40,8.09;3,36.85,273.65,221.20,8.09;3,36.85,284.09,34.75,8.09" xml:id="d8-p1-s9">Fisher's exact test was used to compare the treatment groups on the proportion of responders and remitters at endpoint.</s><s coords="3,73.42,284.09,184.66,8.09;3,36.85,294.57,221.16,8.09;3,36.85,305.00,221.20,8.09;3,36.85,315.49,91.60,8.09" xml:id="d8-p1-s10">Responders demonstrated an at least 50% improvement in YMRS scores from baseline to week 1 and endpoint and remitters had an YMRS score of 7 or less at endpoint <ref type="bibr" coords="3,36.85,315.49,87.68,8.09" target="#b5">(Chengappa et al., 2003)</ref>.</s></p></div>
<div xml:id="d9"><head n="8." xml:id="d9-h1">Results</head><p xml:id="d9-p1"><s coords="3,48.81,357.50,209.24,8.09" xml:id="d9-p1-s1">Sixty potential study candidates were initially identified.</s><s coords="3,36.85,367.99,221.21,8.09" xml:id="d9-p1-s2">However, 20 patients did not meet study inclusion criteria.</s><s coords="3,36.85,378.42,221.19,8.09" xml:id="d9-p1-s3">Therefore, 40 bipolar patients were randomized in this study.</s><s coords="3,36.85,388.91,221.16,8.09;3,36.85,399.34,221.20,8.09;3,36.85,409.83,221.15,8.09;3,36.85,420.32,160.23,8.09" xml:id="d9-p1-s4">One patient from the tamoxifen group and two from the placebo group were dropped out of the study, leaving 37 patients who met the DSMIV criteria for mania and currently experiencing a manic episode (Fig. <ref type="figure" coords="3,186.80,420.32,3.42,8.09" target="#fig_0">1</ref>).</s><s coords="3,202.57,420.32,55.45,8.09;3,36.85,430.75,221.14,8.09;3,36.85,441.24,221.17,8.09;3,36.85,451.67,103.56,8.09" xml:id="d9-p1-s5">No significant differences were identified between patients randomly assigned to the group A or B condition with regard to basic demographic data (Table <ref type="table" coords="3,130.51,451.67,3.30,8.09" target="#tab_0">1</ref>).</s></p></div>
<div xml:id="d10"><head n="9." xml:id="d10-h1">Tamoxifen versus placebo: YMRS</head><p xml:id="d10-p1"><s coords="3,48.81,493.73,209.24,8.09;3,36.85,504.17,66.80,8.09" xml:id="d10-p1-s1">The mean ± SD scores of the two groups of patients are shown in Fig. <ref type="figure" coords="3,97.17,504.17,3.24,8.09" target="#fig_1">2</ref>.</s><s coords="3,108.91,504.17,149.13,8.09;3,36.85,514.65,221.19,8.09;3,36.85,525.08,202.58,8.09" xml:id="d10-p1-s2">There were no significant differences between the two groups on day 0 (baseline) in the Young Mania Rating Scale (t =012, df =38 and p = 0.79).</s><s coords="3,244.57,525.08,13.44,8.09;3,36.85,535.57,221.17,8.09;3,36.85,546.00,221.21,8.09;3,36.85,556.49,100.01,8.09" xml:id="d10-p1-s3">The difference between the two protocols was significant as indicated by the effect of group, the between subjects factor (F = 5.41, df =1, p = 0.02).</s><s coords="3,140.60,556.49,117.48,8.09;3,36.85,566.92,221.19,8.09;3,36.85,577.41,221.22,8.09;3,36.85,587.84,35.04,8.09" xml:id="d10-p1-s4">The behavior of the two treatments was not similar across time (groups-by-time interaction, Greenhouse-Geisser correction; F = 4.00, df = 2.10 and p = 0.02).</s><s coords="3,74.10,587.84,183.97,8.09;3,36.85,598.33,221.21,8.09;3,36.85,608.76,160.44,8.40" xml:id="d10-p1-s5">In addition, a one-way repeated measures analysis of variance showed a significant effect of both protocols on the Young Mania Rating Scale (p b 0.0001).</s><s coords="3,200.58,608.76,57.51,8.09;3,36.85,619.25,221.23,8.09;3,36.85,629.68,221.20,8.09" xml:id="d10-p1-s6">In both groups, post hoc comparisons showed a significant change compared with baseline from day 7 on the Young Mania Rating Scale.</s><s coords="3,36.85,640.17,221.19,8.09;3,36.85,650.60,204.69,8.09" xml:id="d10-p1-s7">The difference between the two protocols was significant at the endpoint (day 42) (t = 3.23, df = 38; p = 0.002).</s><s coords="3,244.69,650.60,13.36,8.09;3,36.85,661.09,221.11,8.09;3,36.85,671.52,221.23,8.09;3,36.85,682.01,79.78,8.09" xml:id="d10-p1-s8">The changes at the endpoint compared with baseline were -29.80 ± 7.36 (mean ± SD) and -23.05 ± 7.95 for groups A and B, respectively.</s><s coords="3,119.62,682.01,138.48,8.09;3,281.93,231.81,221.21,8.09;3,281.93,242.24,221.20,8.09;3,281.93,252.73,69.37,8.09" xml:id="d10-p1-s9">A significant difference was observed in the change of scores of the Young Mania Rating Scale on day 42 compared to baseline in the two groups (t = 2.78, df = 38, p = 0.008).</s><s coords="3,353.59,252.73,149.55,8.09;3,281.93,263.17,221.14,8.09;3,281.93,273.65,221.19,8.09;3,281.93,284.09,221.20,8.09;3,281.93,294.57,221.21,8.09;3,281.93,305.01,221.22,8.09" xml:id="d10-p1-s10">There was significant difference between the two treatments in terms of percentage of responders at week 1 and endpoint (at least 50% reduction in the Young Mania Rating Scale score) (tamoxifen group 50 %, 10 of 20 and placebo group: 15%, 3 of 20; p = 0.04) (tamoxifen group 95%, 19 of 20 and placebo group 70%, 14 of 20; p = 0.09).</s><s coords="3,281.93,315.49,221.17,8.09;3,281.93,325.92,221.19,8.09;3,281.93,336.41,164.89,8.09" xml:id="d10-p1-s11">Ninety percent of the patients in the tamoxifen group (18 of 20) and 55% in the placebo group (11 out 20) were remitted after 6 weeks (an YMRS score of 7 or less).</s><s coords="3,450.14,336.41,53.00,8.09;3,281.93,346.84,95.31,8.09" xml:id="d10-p1-s12">The difference was significant (p = 0.03).</s></p></div>
<div xml:id="d11"><head n="10." xml:id="d11-h1">Tamoxifen versus placebo: PANSS and HAMD-17</head><p xml:id="d11-p1"><s coords="3,293.90,388.85,209.24,8.09;3,281.93,399.29,198.04,8.09" xml:id="d11-p1-s1">The mean ± SD scores of the two groups of patients on PANSS and HAMD-17 at week 0 are shown in Table <ref type="table" coords="3,473.55,399.29,3.21,8.09" target="#tab_1">2</ref>.</s><s coords="3,482.40,399.29,20.74,8.09;3,281.93,409.77,221.21,8.09;3,281.93,420.21,221.20,8.09;3,281.93,430.69,221.19,8.09" xml:id="d11-p1-s2">There were no significant differences between the two groups on day 0 (baseline) in the PANSS and HAMD-17 (t = 0.20; df = 38; p = 0.84 and t = 0.40; df = 38; p = 0.68 respectively).</s></p><p xml:id="d11-p2"><s coords="3,293.89,441.12,209.25,8.09;3,281.93,451.61,221.17,8.09;3,281.93,462.04,35.04,8.09" xml:id="d11-p2-s1">A significant difference was observed on the PANSS total score at week 6 in the two groups (t = 2.55; df = 38; p = 0.01).</s><s coords="3,321.33,462.04,181.76,8.09;3,281.93,472.53,221.16,8.09;3,281.93,482.96,35.04,8.09" xml:id="d11-p2-s2">The difference between the two groups in the HAMD-17 at week 6 was not significant (t = 0.20; df = 38; p = 0.84).</s></p></div>
<div xml:id="d12"><head n="11." xml:id="d12-h1">Clinical complications and side effects</head><p xml:id="d12-p1"><s coords="3,293.89,524.97,191.27,8.09" xml:id="d12-p1-s1">Fifteen side effects were observed over the trial.</s><s coords="3,489.76,524.97,13.36,8.09;3,281.93,535.40,221.20,8.09;3,281.93,545.89,221.25,8.09;3,281.93,556.32,164.90,8.09" xml:id="d12-p1-s2">The difference between the two groups in the frequency of side effects was not significant except for fatigue that occurred more often in the tamoxifen group (Table <ref type="table" coords="3,436.99,556.32,3.28,8.09">3</ref>).</s></p></div>
<div xml:id="d13"><head n="12." xml:id="d13-h1">Discussion</head><p xml:id="d13-p1"><s coords="3,293.89,598.33,209.24,8.09;3,281.93,608.76,221.16,8.09;3,281.93,619.25,95.80,8.09" xml:id="d13-p1-s1">The present study shows Young Mania Rating Scale scores improvement with tamoxifen over the 6-week double-blind placebo-controlled trial.</s><s coords="3,383.27,619.25,119.79,8.09;3,281.93,629.68,221.16,8.09;3,281.93,640.17,221.20,8.09;3,281.93,650.60,91.52,8.09" xml:id="d13-p1-s2">Clinical characteristics of the patients, such as sex, age, and duration of illness, did not differ between the groups and cannot explain differences in the therapeutic outcome.</s><s coords="3,375.64,650.60,127.52,8.09;3,281.93,661.09,221.20,8.09;3,281.93,671.52,136.35,8.09" xml:id="d13-p1-s3">Therapy with 80 mg/day of tamoxifen was well tolerated, and no clinically important side effects except fatigue were observed.</s><s coords="3,420.99,671.52,82.17,8.09;3,281.93,682.01,221.21,8.09;4,41.22,399.63,221.20,8.09;4,41.22,410.11,221.23,8.09;4,41.22,420.55,221.17,8.09;4,41.22,431.03,132.07,8.09" xml:id="d13-p1-s4">The efficacy of tamoxifen to obtain a greater improvement in patients with mania  <ref type="bibr" coords="4,41.22,399.63,25.28,8.09">(2000)</ref> in a single-blind, open-label, add-on (some patients were administered no other medications) study on 7 subjects, reported that tamoxifen may have efficacy in the treatment of acute mania <ref type="bibr" coords="4,89.23,431.03,80.14,8.09">(Bebchuk et al., 2000)</ref>.</s><s coords="4,176.26,431.03,86.13,8.09;4,41.21,441.46,98.09,8.09" xml:id="d13-p1-s5">The maximal dosage of tamoxifen was 80 mg/day.</s><s coords="4,142.46,441.46,119.97,8.09;4,41.21,451.95,221.20,8.09;4,41.21,462.38,221.24,8.40;4,41.21,472.87,221.23,8.09;4,286.30,368.16,221.16,8.09;4,286.30,378.65,169.49,8.09" xml:id="d13-p1-s6">In a 4-week, three-arm, doubleblind, lithium and/or valproate add-on study, in women involving 13 women with a 40 mg fixed dose of tamoxifen compared with medroxyprogesterone or placebo, tamoxifen 40 mg/day was found to have superior anti-manic effects compared to placebo <ref type="bibr" coords="4,369.35,378.65,82.52,8.09" target="#b8">(Kulkarni et al., 2006)</ref>.</s><s coords="4,459.55,378.65,47.99,8.09;4,286.30,389.08,221.15,8.09;4,286.30,399.57,221.22,8.09" xml:id="d13-p1-s7">In a 3-week, double-blind, placebo-controlled study (n = 16), tamoxifen (up to 140 mg/day) was superior to placebo in acute mania.</s><s coords="4,286.30,410.00,221.21,8.40;4,286.30,420.49,94.26,8.09" xml:id="d13-p1-s8">Lorazepam (up to 2 mg/day) was permitted for the first 10 days of the blinded phase.</s><s coords="4,382.56,420.49,124.93,8.09;4,286.30,430.92,117.69,8.09" xml:id="d13-p1-s9">Significant improvement was seen as early as day 5 in YMRS scores.</s><s coords="4,405.98,430.92,101.49,8.09;4,286.30,441.41,173.86,8.09" xml:id="d13-p1-s10">No significant improvement was seen in MADRS scores <ref type="bibr" coords="4,386.02,441.41,70.22,8.09">(Zarate et al., 2007)</ref>.</s><s coords="4,298.26,451.89,209.16,8.09;4,286.30,462.33,221.23,8.09;4,286.30,472.81,104.95,8.09" xml:id="d13-p1-s11">In a recent 3-week, double-blind, placebo-controlled study (n = 66), tamoxifen (up to 80 mg/day) was superior to placebo in acute mania.</s><s coords="4,395.83,472.81,111.71,8.09;4,286.30,483.25,221.17,8.09;4,286.30,493.73,45.22,8.09" xml:id="d13-p1-s12">Lorazepam (up to 5 mg/day) was permitted for the entire duration of the study <ref type="bibr" coords="4,483.47,483.25,24.00,8.09;4,286.30,493.73,41.29,8.09" target="#b9">(Yildiz et al., 2008)</ref>.</s><s coords="4,333.81,493.73,173.72,8.09;4,286.30,504.16,41.53,8.09" xml:id="d13-p1-s13">Significant improvement in YMRS was reported at week 3.</s><s coords="4,332.22,504.16,175.23,8.09;4,286.30,514.65,221.16,8.09;5,36.85,242.64,102.72,8.09" xml:id="d13-p1-s14">However, the present study added tamoxifen to lithium and the follow-up was longer compared to   previously reported studies.</s><s coords="5,142.35,242.64,115.67,8.40;5,36.85,253.13,221.16,8.09;5,36.85,263.56,221.21,8.09;5,36.85,274.05,221.16,8.09;5,36.85,284.48,221.21,8.09;5,36.85,294.97,221.24,8.09;5,36.85,305.40,23.51,8.09" xml:id="d13-p1-s15">The most important findings of this study are that tamoxifen may induce a rapid effect as early as day 7. Based on our hypothesis, attenuating PKC activity not only represents a very important facet in the treatment of manic behavior, but that a direct acting PKC inhibitor would also have rapid effects <ref type="bibr" coords="5,187.88,294.97,70.22,8.09;5,36.85,305.40,19.59,8.09" target="#b11">(Zarate and Manji, 2009)</ref>.</s><s coords="5,62.99,305.40,195.04,8.09;5,36.85,315.89,221.24,8.09;5,36.85,326.32,23.51,8.09" xml:id="d13-p1-s16">The main limitation of this study is that tamoxifen is an antagonist of estrogen receptor as well <ref type="bibr" coords="5,190.99,315.89,67.10,8.09;5,36.85,326.32,19.59,8.09" target="#b11">(Zarate and Manji, 2009)</ref>.</s><s coords="5,65.31,326.32,192.71,8.09;5,36.85,336.81,221.17,8.09;5,36.85,347.24,132.58,8.09" xml:id="d13-p1-s17">The results demonstrate that the combination of tamoxifen with lithium was superior to lithium alone for rapid reduction of manic symptoms.</s></p></div><figure xml:id="fig_0" coords="4,246.67,337.47,55.33,6.47;4,102.10,50.29,344.48,276.61"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s coords="4,246.67,337.80,17.88,6.14">Fig. 1.</s><s coords="4,266.46,337.47,35.55,6.47">Trial profile.</s></p></div></figDesc><graphic coords="4,102.10,50.29,344.48,276.61" type="bitmap" /></figure>
<figure xml:id="fig_1" coords="4,41.22,666.17,221.13,6.47;4,41.22,674.73,221.16,6.72;4,41.22,683.30,148.27,6.47;4,48.93,503.32,205.88,152.33"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s coords="4,41.22,666.17,221.13,6.47">Fig. 2. Mean ± SD of the two protocols on the Young Mania Rating Scale.</s><s coords="4,41.22,674.73,141.60,6.72">**p b 0.01; ***p b 0.001 and ns = nonsignificant.</s><s coords="4,186.80,674.73,75.57,6.47;4,41.22,683.30,148.27,6.47">a indicates week versus baseline and b indicates tamoxifen versus placebo.</s></p></div></figDesc><graphic coords="4,48.93,503.32,205.88,152.33" type="bitmap" /></figure>
<figure type="table" xml:id="tab_0" coords="3,36.85,55.07,460.29,138.63"><head>Table 1</head><label>1</label><figDesc><div><p><s coords="3,36.85,63.30,40.03,6.47;4,66.61,368.28,7.38,8.09">Baseline data.to</s><s coords="4,76.88,368.28,185.53,8.09;4,41.22,378.71,153.87,8.09">support the hypothesis that PKC inhibition has an important role in the treatment of mania.</s><s coords="4,197.74,378.71,64.64,8.09;4,41.22,389.19,169.98,8.09">The results of the present study are in line with 4 published trials.</s><s coords="4,212.83,389.20,49.59,8.09">Bebchuk et al.</s></p></div></figDesc><table coords="3,42.80,79.97,454.33,113.73"><row><cell /><cell>Tamoxifen group</cell><cell>Placebo group</cell><cell>p</cell></row><row><cell>Gender</cell><cell>Male: 8, Female: 12</cell><cell>Male: 7, Female: 13</cell><cell>1.00</cell></row><row><cell>Age (Mean ± SD)</cell><cell>30.45 ± 9.68 (year)</cell><cell>30.95 ± 8.66 (year)</cell><cell>0.86</cell></row><row><cell>Marital status</cell><cell>Single: 11, married: 6, divorced: 3</cell><cell>Single: 12, married: 7, divorced: 1</cell><cell>1.00</cell></row><row><cell>Level of education</cell><cell>Under diploma: 11, diploma: 6, higher diploma: 3</cell><cell>Under diploma: 12, diploma: 7, higher diploma: 1</cell><cell>1.00</cell></row><row><cell>Length of illness</cell><cell>9.25 ± 8.68 (year)</cell><cell>8.90 ± 5.333 (year)</cell><cell>0.88</cell></row><row><cell>Current episode, days</cell><cell>33.25 ± 18.65</cell><cell>34.12 ± 19.14</cell><cell>0.87</cell></row><row><cell>Smoking</cell><cell>10</cell><cell>9</cell><cell>1.00</cell></row><row><cell>Current episode</cell><cell>Mania: 5, psychotic: 14, mixed: 1</cell><cell>Mania: 6, psychotic: 13, mixed: 1</cell><cell>1.00</cell></row><row><cell>Previous medication use</cell><cell>Lithium: 20, valproate: 10, carbamazepine: 8,</cell><cell>Lithium: 20, valproate: 11, carbamazepine:6,</cell><cell>1.00</cell></row><row><cell /><cell>olanzapine: 8, risperidone:5, typical antipsychotic: 5</cell><cell>olanzapine: 10, risperidone:7, typical antipsychotic: 6</cell><cell /></row><row><cell>Life time alcohol and drug use</cell><cell>13</cell><cell>12</cell><cell>1.00</cell></row><row><cell>Previous number of episode</cell><cell>Mania: 6, depressive: 2, mixed: 0</cell><cell>Mania: 7, depressive: 1, mixed: 0</cell><cell>1.00</cell></row></table><note><p><s coords="4,41.22,368.28,22.56,8.09">seems</s></p></note></figure>
<figure type="table" xml:id="tab_1" coords="4,286.30,548.64,221.16,136.65"><head>Table 2</head><label>2</label><figDesc><div><p><s coords="4,286.30,556.87,221.16,6.47;4,286.30,565.43,27.80,6.47">Summary of primary and secondary outcome measurers at baseline and endpoint.</s></p></div></figDesc><table coords="4,292.25,580.06,209.21,105.23"><row><cell /><cell>Week 0</cell><cell>p</cell><cell>Week 6</cell><cell>p</cell></row><row><cell cols="2">Young Mania Rating Scale</cell><cell /><cell /><cell /></row><row><cell>Lithium + tamoxifen</cell><cell>32.95 ± 7.41</cell><cell>0.79</cell><cell>3.15 ± 1.78</cell><cell>0.002</cell></row><row><cell>Lithium + placebo</cell><cell>32.40 ± 6.07</cell><cell /><cell>9.45 ± 8.50</cell><cell /></row><row><cell cols="4">Positive and Negative Syndrome Scale (total score)</cell><cell /></row><row><cell>Lithium + tamoxifen</cell><cell>75.10 ± 18.65</cell><cell>0.84</cell><cell>45.16 ± 11.85</cell><cell>0.01</cell></row><row><cell>Lithium + placebo</cell><cell>73.90 ± 19.16</cell><cell /><cell>56.32 ± 15.42</cell><cell /></row><row><cell cols="2">Hamilton Depression Rating Scale-17</cell><cell /><cell /><cell /></row><row><cell>Lithium + tamoxifen</cell><cell>7.15 ± 2.20</cell><cell>0.68</cell><cell>6.18 ± 1.95</cell><cell>0.84</cell></row><row><cell>Lithium + placebo</cell><cell>7.45 ± 2.33</cell><cell /><cell>6.30 ± 1.80</cell><cell /></row></table></figure>
			<note place="foot" xml:id="foot_0"><p><s coords="2,174.27,35.05,200.14,6.15">Z.Amrollahi et al. / Journal of Affective Disorders 129 (2011) 327-331</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgments</head><p><s coords="5,48.81,452.86,209.25,8.09;5,36.85,463.35,143.34,8.09">This study was <rs type="person">Dr. Zohreh Amrollahi</rs>'s postgraduate thesis toward the <rs type="funder">Iranian Board of Psychiatry</rs>.</s></p></div>
			</div>
			<div type="funding">
<div><head>Role of funding source</head><p><s coords="5,48.81,376.13,209.20,6.47;5,36.85,384.69,165.79,6.47">This study was supported by a grant from <rs type="funder">Tehran University of Medical Sciences</rs> to <rs type="person">Prof. Shahin Akhondzadeh</rs> (Grant No: <rs type="grantNumber">6965</rs>).</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_naXtzFE">
					<idno type="grant-number">6965</idno>
				</org>
			</listOrg>
			<div type="annex">
<div><head>Conflict of interest statement</head><p><s coords="5,48.81,412.30,99.10,6.47">We declare no conflict of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct coords="5,281.93,73.96,221.12,6.47;5,293.90,81.95,209.23,6.47;5,293.90,89.89,209.15,6.47;5,293.90,97.88,58.57,6.47" xml:id="b0">
	<analytic>
		<title level="a" type="main">Is it time to have another look at lithium maintenance therapy in bipolar disorder?</title>
		<author>
			<persName><forename type="first">S</forename><surname>Akhondzadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Emamian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ahmadi-Abhari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Shabestari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dadgarnejad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prog. Neuropsychopharmacol. Biol. Psychiatry</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1011" to="1017" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="5,281.93,105.88,221.11,6.47;5,293.90,113.81,209.17,6.47;5,293.90,121.81,209.16,6.47;5,293.90,129.75,85.84,6.47" xml:id="b1">
	<analytic>
		<title level="a" type="main">Ritanserin as an adjunct to lithium and haloperidol for the treatment of medicationnaive patients with acute mania: a double blind and placebo controlled trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Akhondzadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mohajari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Mohammadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Amini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Psychiatry</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="3" to="7" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="5,281.93,137.74,221.11,6.47;5,293.90,145.73,209.17,6.47;5,293.90,153.67,209.13,6.47;5,293.90,161.66,126.18,6.47" xml:id="b2">
	<analytic>
		<title level="a" type="main">Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebocontrolled trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Akhondzadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Milajerdi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Amini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tehrani-Doost</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bipolar Disord</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="485" to="489" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="5,281.93,169.60,221.19,6.47;5,293.90,177.59,209.18,6.47;5,293.90,185.53,91.21,6.47" xml:id="b3">
	<monogr>
		<title level="m" type="main">Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition</title>
		<imprint>
			<date type="published" when="2000">2000</date>
			<publisher>American Psychiatric Association</publisher>
			<pubPlace>Washington, DC</pubPlace>
		</imprint>
	</monogr>
	<note>Text Revision</note>
</biblStruct>

<biblStruct coords="5,281.93,193.52,221.15,6.47;5,293.90,201.52,209.19,6.47;5,293.90,209.45,186.56,6.47" xml:id="b4">
	<analytic>
		<title level="a" type="main">A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>B E B C H U K</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>A R F K E N</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch. Gen. Psychiatry</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="95" to="97" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="5,281.93,217.45,221.16,6.47;5,293.89,225.38,209.21,6.47;5,293.89,233.38,209.21,6.47;5,293.89,241.37,12.42,6.47;5,281.93,249.31,221.13,6.47;5,293.89,257.30,209.19,6.47;5,293.89,265.24,128.00,6.47" xml:id="b5">
	<analytic>
		<title level="a" type="main">A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Chengappa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">N</forename><surname>Yatham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gershon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kupfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Diazgranados</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Zarate</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr. Psychiatry Rep</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="510" to="519" />
			<date type="published" when="2003">2003. 2008</date>
		</imprint>
	</monogr>
	<note>Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania Bipolar Disord.</note>
</biblStruct>

<biblStruct coords="5,281.93,273.23,221.11,6.47;5,293.90,281.23,58.81,6.47" xml:id="b6">
	<analytic>
		<title level="a" type="main">A rating scale for depression</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hamilton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurol. Neurosurg. Psychiatry</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="62" to="66" />
			<date type="published" when="1960">1960</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="5,281.93,289.16,221.19,6.47;5,293.90,297.16,155.10,6.47" xml:id="b7">
	<analytic>
		<title level="a" type="main">The positive and negative syndrome scale for schizophrenia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Kay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fiszbein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Opler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr. Bull</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="261" to="276" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="5,281.93,305.09,221.18,6.47;5,293.89,313.09,209.22,6.47;5,293.89,321.02,209.15,6.47;5,293.89,329.02,118.82,6.47" xml:id="b8">
	<analytic>
		<title level="a" type="main">A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kulkarni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Garland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Scaffidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Headey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>De Castella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fitzgerald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychoneuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="543" to="547" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="5,281.93,337.01,221.12,6.47;5,293.90,344.95,209.15,6.47;5,293.90,352.94,187.87,6.47" xml:id="b9">
	<analytic>
		<title level="a" type="main">Protein kinase C inhibition in the treatment of mania: a double-blind, placebocontrolled trial of tamoxifen</title>
		<author>
			<persName><forename type="first">A</forename><surname>Yildiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Guleryuz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Ankerst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ongür</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Renshaw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch. Gen. Psychiatry</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="255" to="263" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="5,281.93,360.88,221.17,6.47;5,293.89,368.87,208.16,6.47" xml:id="b10">
	<analytic>
		<title level="a" type="main">A rating scale for mania: reliability, validity and sensitivity</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Biggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Ziegler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Meyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br. J. Psychiatry</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="638" to="642" />
			<date type="published" when="1978">1978</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="5,281.93,376.87,221.18,6.47;5,293.89,384.80,209.17,6.47;5,293.89,392.80,27.03,6.47" xml:id="b11">
	<analytic>
		<title level="a" type="main">Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Zarate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Manji</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CNS Drugs</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="569" to="582" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="5,281.93,400.73,221.09,6.47;5,293.89,408.73,209.15,6.72;5,293.89,416.66,209.15,6.47;5,293.89,424.66,41.94,6.47" xml:id="b12">
	<monogr>
		<title />
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Zarate</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Carlson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Quiroz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jolkovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Luckenbaugh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2007">2 0 0 7</date>
			<biblScope unit="page">561</biblScope>
		</imprint>
	</monogr>
	<note>E f ficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 9</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>